Taligen Therapeutics Inc.

Taligen Therapeutics Inc. (Taligen) is a privately held biotechnology company that is engaged in the development of innovative therapeutics for the treatment of inflammatory and immune diseases. It has developed a strong portfolio of pipeline candidates for these diseases which mainly include TA106, a monoclonal antibody developed as an inhaled product candidate for the treatment of asthma and TT30, which delivers complement inhibitors, such as Factor H to sites, where complement activation occurs and drives inflammation. The company currently focuses on developing new therapeutics using its proprietary technology to treat inflammatory diseases. Taligen was incorporated in the year 2004 and is headquartered at Cambridge in Massachusetts, the US.

Street: 
245 First Street
City: 
Cambridge
Postcode: 
02142
Federal State : 
United States
WebSite: 
www.taligentherapeutics.com
Fax: 
1-617-2993201

Company Index Score

Current Index Score Historical Index Score
  • Taligen Therapeutics Inc. currently scores 50 % in the index.
  • Taligen Therapeutics Inc. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Taligen Therapeutics Inc. is currently ranked 1 out of 4535 companies. This is in the top 0.022 % percent of Pharmaceutical companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets